Key facts
- This page summarizes Mark Oldakowski's Form 4 filing for Bionano Genomics, Inc. (BNGO).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 05 Jun 2024, 17:49.
Mark Oldakowski - 03 Jun 2024 Form 4 Insider Report for Bionano Genomics, Inc. (BNGO)
- Reporting relationship
- CHIEF OPERATING OFFICER
- Issuer ticker
- BNGO
- Reported as of
- 03 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 05 Jun 2024, 17:49:36 UTC
- Prior SEC filing
- 05 Mar 2024
- Next SEC filing
- 13 Sep 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jonathan V. Dixon, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Mark Oldakowski filed Form 4 for Bionano Genomics, Inc. (BNGO) on 05 Jun 2024.
Change
- Previous filing in this sequence was filed on 05 Mar 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BNGO
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +16,000
- Change %
- +33%
- Price
- $0.000000
- Shares after
- 64,698
- Date
- 03 Jun 2024
- Ownership
- Direct
- Footnotes
- F1, F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BNGO
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +75,000
- Change %
- Price
- $0.000000
- Shares after
- 75,000
- Date
- 03 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 75,000
- Exercise price
- $0.9300
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Represents restricted stock unit award granted under the Issuer's 2018 Equity Incentive Plan.
Footnote F2
The shares subject to the RSUs vest 1/4th annually beginning on the one-year anniversary of the grant date.
Footnote F3
Includes 54 shares acquired under the Issuer's 2018 Employee Stock Purchase Plan (the "ESPP") on June 9, 2023.
Footnote F4
The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of June 3, 2024 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date.